ALPMY Quote, Financials, Valuation and Earnings

Healios KK has a net margin of 7.95% compared to Astellas Pharma's net margin of -107.23%. Astellas Pharma's return on equity of 0.97% beat Healios KK's return on equity of -137.21%.

Astellas Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Astellas Pharma has higher upside potential than Healios KK, analysts believe Astellas Pharma is more attractive than Healios KK.

Astellas Pharma has a beta of 0.330, which suggesting that the stock is 66.957% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Astellas Pharma has a quarterly dividend of $0.25 per share corresponding to a yield of 4.88%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astellas Pharma pays 684.38% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.

Astellas Pharma quarterly revenues are $3B, which are larger than Healios KK quarterly revenues of $3.2M. Astellas Pharma's net income of $241.2M is higher than Healios KK's net income of -$3.4M. Notably, Astellas Pharma's price-to-earnings ratio is 165.64x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma is 1.52x versus 22.75x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of 7.95% compared to Astellas Pharma's net margin of -5.57%. Astellas Pharma's return on equity of 0.97% beat PeptiDream's return on equity of 34.66%.

Astellas Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Astellas Pharma has higher upside potential than PeptiDream, analysts believe Astellas Pharma is more attractive than PeptiDream.

Astellas Pharma has a beta of 0.330, which suggesting that the stock is 66.957% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.804, suggesting its less volatile than the S&P 500 by 19.554%.

Astellas Pharma has a quarterly dividend of $0.25 per share corresponding to a yield of 4.88%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astellas Pharma pays 684.38% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.

Astellas Pharma quarterly revenues are $3B, which are larger than PeptiDream quarterly revenues of $36.8M. Astellas Pharma's net income of $241.2M is higher than PeptiDream's net income of -$2.1M. Notably, Astellas Pharma's price-to-earnings ratio is 165.64x while PeptiDream's PE ratio is 21.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma is 1.52x versus 7.43x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of 7.95% compared to Astellas Pharma's net margin of 12.96%. Astellas Pharma's return on equity of 0.97% beat Nxera Pharma's return on equity of -5.58%.

Astellas Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Astellas Pharma has higher upside potential than Nxera Pharma, analysts believe Astellas Pharma is more attractive than Nxera Pharma.

Astellas Pharma has a beta of 0.330, which suggesting that the stock is 66.957% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.401, suggesting its less volatile than the S&P 500 by 59.86%.

Astellas Pharma has a quarterly dividend of $0.25 per share corresponding to a yield of 4.88%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astellas Pharma pays 684.38% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.

Astellas Pharma quarterly revenues are $3B, which are larger than Nxera Pharma quarterly revenues of $62.4M. Astellas Pharma's net income of $241.2M is higher than Nxera Pharma's net income of $8.1M. Notably, Astellas Pharma's price-to-earnings ratio is 165.64x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma is 1.52x versus 2.95x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of 7.95% compared to Astellas Pharma's net margin of 7.83%. Astellas Pharma's return on equity of 0.97% beat Takeda Pharmaceutical's return on equity of 4.01%.

Astellas Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $15.73 which suggests that it could grow by 17.86%. Given that Takeda Pharmaceutical has higher upside potential than Astellas Pharma, analysts believe Takeda Pharmaceutical is more attractive than Astellas Pharma.

Astellas Pharma has a beta of 0.330, which suggesting that the stock is 66.957% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.642%.

Astellas Pharma has a quarterly dividend of $0.25 per share corresponding to a yield of 4.88%. Takeda Pharmaceutical offers a yield of 4.63% to investors and pays a quarterly dividend of $0.33 per share. Astellas Pharma pays 684.38% of its earnings as a dividend. Takeda Pharmaceutical pays out 199.34% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Astellas Pharma quarterly revenues are $3B, which are smaller than Takeda Pharmaceutical quarterly revenues of $7.9B. Astellas Pharma's net income of $241.2M is lower than Takeda Pharmaceutical's net income of $619.7M. Notably, Astellas Pharma's price-to-earnings ratio is 165.64x while Takeda Pharmaceutical's PE ratio is 22.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma is 1.52x versus 1.41x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.